{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 38,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/3",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.14,
        "y": 0.47
      },
      "kind": "list",
      "text": "Validating Strategic Partnerships. Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing a canine efficacy study with V-VET1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0103754e-3332-4294-b586-fea3b833c3ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.14,
        "y": 0.78
      },
      "kind": "list",
      "text": "Estimated Billion Dollar Plus Annual Market Opportunity in the U.S. Potential beyond this in numerous clinical settings",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b632227-c39a-4942-b18e-b11e0e43911e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.14,
        "y": 0.32
      },
      "kind": "list",
      "text": "CHOICE™ Platform; Broad and Diverse Discovery Engine. Library with over 500 novel vaccinia strains and 110+ transgenes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "689c0158-6303-4b95-bd27-78490a89b941",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.14,
        "y": 0.17
      },
      "kind": "list",
      "text": "Olvi-Vec: De-risked late-stage Clinical Program. Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa256ad9-eb75-4d6f-a221-91e144753e32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.14,
        "y": 0.65
      },
      "kind": "list",
      "text": "Focused Commercial Strategy. US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bccb1d1c-d327-4483-95d4-9446b5ff9ea5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cfbacc0-73bc-4a1b-b746-2d0742788d52",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "cd8bb61a-bff7-4104-8cd8-c051b50b66c8",
      "evidence": "Validating Strategic Partnerships. Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 1,
      "beatId": "e444b487-fcb2-4bdd-9b87-8dd886121483",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The initial slides introduce the problem and highlight the limitations of current oncolytic immunotherapies.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}